Aligos TherapeuticsALGS
13F holders, Q3 2024 (September 30)27holders
1famous investor
$8.66avg. 13F price*
At the end of Q3 2024, 27 institutions reported holding Aligos Therapeutics Inc. (ALGS) in their 13F filings. The largest holders were Armistice Capital, LLC ($2.7M), EcoR1 Capital, LLC ($2.2M) and Deep Track Capital, LP ($2.1M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Aligos Therapeutics Inc.
- CUSIP
- 01626L204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1K |
| Exits | 0 | $0 |
Ownership 27 holders
| Armistice Capital, LLC | 0.07% | Add +8.6% | 315,095 | $2.7M |
| EcoR1 Capital, LLC | 0.08% | No change | 255,573 | $2.2M |
| Deep Track Capital, LP | 0.07% | No change | 244,110 | $2.1M |
| Adage Capital Partners Gp, L.L.C. | 0.00% | Add +9.4% | 218,813 | $1.9M |
| Vivo Capital, LLC | 0.10% | No change | 141,879 | $1.2M |
| Woodline Partners LP | 0.01% | Add +332.8% | 91,971 | $796K |
| Baker Bros. Advisors LP | 0.01% | No change | 83,055 | $719K |
| HHLR Advisors, LTD. | 0.01% | Reduce -38.9% | 76,247 | $660K |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 0.01% | Add +67.7% | 67,096 | $581K |
| Vanguard Group Inc. | 0.00% | No change | 63,814 | $553K |
| Acadian Asset Management LLC | 0.00% | Reduce -7.8% | 30,597 | $263K |
| Silverarc Capital Management, LLC | 0.05% | No change | 26,219 | $227K |
| Geode Capital Management, LLC | 0.00% | Add +48.2% | 24,056 | $208K |
| Renaissance Technologies | 0.00% | Reduce -56.3% | 13,443 | $116K |
| Charles Schwab Investment Management Inc. | 0.00% | Add +854.3% | 11,980 | $104K |
| Qube Research & Technologies Ltd | 0.00% | Add +13683650.0% | 10,947 | $95K |
| BlackRock, Inc. | 0.00% | — | 9,067 | $79K |
| Bank of America Corp. | 0.00% | Reduce -79.0% | 6,851 | $59K |
| Cwm, LLC | 0.00% | No change | 675 | $6K |
| Osaic Holdings, Inc. | 0.00% | No change | 220 | $2K |
| Morgan Stanley | 0.00% | Add +1.5% | 134 | $1K |
| AlphaMark Advisors, LLC | 0.00% | New | 100 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -98.4% | 30 | $260 |
| JPMorgan Chase & Co. | 0.00% | Reduce -4.0% | 26 | $225 |
| UBS Group AG | 0.00% | Reduce -3.3% | 14 | $121 |
| Elevation Wealth Partners, LLC | 0.00% | No change | 4 | $35 |
| BNP Paribas Financial Markets | 0.00% | New | 3 | $26 |
"% of holder's portfolio" is ALGS's weight in each manager's 13F, not the share of Aligos Therapeutics Inc. the manager owns.